. Podoplanin is involved in UM-UC-5-induced platelet aggregation. UM-UC-5 cells (5 × 10 4 cells/assay) were incubated with anti-podoplanin neutralizing MS-1 mAb (1, 10 or 100 g/ml) on ice for 30 min, followed by incubation with washed platelets prepared from mouse whole blood (4 × 10 7 platelets/200 l assay) in Tyrode's buffer containing 2% platelet-poor plasma and 250 µM CaCl 2 . Light transmittance of samples was measured to determine aggregation rate using an aggregometer. Aggregation rate (%) compared to control buffer is shown.
UM-UC-5-platelet reactant H226-platelet reactant A549-platelet reactant UM-UC-5-platelet + MS-1 mAb reactant Figure S3 . Detection of growth factors and cytokines secreted during podoplanin-induced platelet aggregation by Bio-Plex analyses. UM-UC-5, H226 and A549 cells (5 × 10 4 cells) were incubated with washed platelets (4 × 10 7 platelets/200 µl assay scale) suspended in Tyrode's buffer containing 2% platelet-poor plasma and 250 µM CaCl 2 . In some experiments, UM-UC-5 cells that were pretreated with anti-podoplanin neutralizing mAb MS-1 (10 g/ml) for 30-40 min on ice were incubated with washed platelets. Concentrations of secreted growth factors and cytokines in the supernatants of tumour-platelet reactants were determined using BioPlex multi-cytokine assays (GII 9-Plex and TGF- 3-Plex). Data (IL-15, IL-18, M-CSF, MIP-2, MIG, VEGF, FGF-basic, LIF, TGF-2, TGF-3) except PDGF-BB and TGF-1 (Fig. 2a) are shown as means ± standard deviation (SD, n = 3 or 5). Supernatant of platelet-UM-UC-5 reactants (2 × 10 8 /ml platelets and 2.5 × 10 5 /ml cells) was added to UM-UC-5 cells (1 ml of supernatant to 3 ml of medium) treated without or with TGFR inhibitor (LY2157299, 10 M) or multi-targeted receptor tyrosine kinase inhibitor (sunitinib, 1 M, Selleck Chemicals) for 1 h in advance. UM-UC-5 was also treated with TGF-1 (5 ng/ml) or PDGF-BB (10 ng/ml, R&D Systems). After 48 h of co-culture, cell images were captured by phase-contrast microscopy (a) and immunoblotted with antibodies to N-cadherin, Claudin-1, podoplanin (PDPN), and TopoII (b). The quantified signal of each band in the immunoblots was normalized by TopoII signal, and relative values against the control sample were indicated. (c) UM-UC-5 and MG63 cells (ATCC) treated without or with sunitinib for 1 h in advance were incubated with PDGF-BB (10 ng/ml). After 30 min of incubation, the cells were lysed and immunoblotted with antibodies to phospho-PDGFR (Tyr1009) (42F9, Cell Signaling Technology), PDGFR (P-20, SantaCruz), phospho-Akt (Ser473) (D9E, Cell Signaling Technology), and Akt (C67E7, Cell Signaling Technology). PDGFR-Akt signal activation was not detected in UM-UC-5, although it was detected and inhibited by sunitinib in MG63. , MS-1 mAb or PG4D2 mAb (100 µg/ml), followed by incubation with platelets (6 × 10 7 /0.2 ml assay) at 37°C. Platelet aggregation was measured using an aggregometer. (c) TGF-β1 concentration in reactants were measured by enzyme-linked immunosorbent assay. All data are shown as means ± standard deviation (SD, n = 3). SCC-015 cells induced TGF-β1 release from platelets, which was suppressed by treatment of the cells with anti-podoplanin neutralizing mAb (clone PG4D2) (100 µg/ml). All data are shown as means ± SD (n = 3). (d) SCC-015 cells were either left untreated (−) or treated with TGF-β neutralizing mAb 1D11 (10 µg/ml) or TGF-βR inhibitor LY2157299 (10 µM) for 2 h. Cells were then incubated with supernatants of PBS (−) or SCC-015-platelet reactants (+) for 48 h. Morphological changes were observed under phase-contrast microscopy. Scale bars indicate 100 µm. (e, f) SCC-015 cells were either left untreated (−) or treated with supernatants of SCC-15-platelet reactants or TGF-β1 (3 ng/ml) for 48 h. (e) Morphological changes were observed under phase-contrast microscopy (left panels). Cells were stained for E-cadherin (green), F-actin (red; phalloidin) and nuclear DNA (blue; Hoechst 33342). Physiological changes of cells were observed under immunofluorescence microscopy (right panels). Scale bars indicate 100 µm. (f) Cell lysates were immunoblotted with antibodies against phospho-Smad3 (pSmad3), Smad3 and TopoII. Mv1Lu was seeded (3 × 10 3 /100 l/well of 96-well plate) and added 50 l of the supernatant of platelet-cell reactant or TGF-1 to the culture on the next day. After 22 h of incubation, BrdU was added and incorporated for 2 h and analyzed by ELlSA. Growth suppression was indicated as the growth distance compared with that of control cells which was added only control Tyrode's buffer to the culture. Means ± SD (n = 3) are indicated. Supernatant of the reactant was prepared using 8 × 10 8 /ml platelets and 4 × 10 6 /ml UM-UC-5 or PBS. For detection of total TGF-, the supernatant was acid-treated; 20 μl of 1 N HCl was added to 100 μl of supernatant, incubated for 10 min at room temperature, and neutralized by adding 20 μl of 1.2 N NaOH /0.5 M HEPES. 
